Why Novo May Be the Real Winner in Obesity Drug Boom
For decades, Novo Nordisk was known mainly within the medical community as a quiet Danish powerhouse in diabetes care. Fast-forward to today, and its brand names are practically pop culture references. Wegovy and Ozempic have become synonymous with rapid weight loss, with late-night comedians, TikTok influencers, and even Hollywood scripts weaving them into conversation. Yet the company’s stock,
» Read more about: Why Novo May Be the Real Winner in Obesity Drug Boom »